Cancer therapy and the heart; the necessity to calibrate risk

Affiliations

¹ Section of Cardio-Oncology, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.
² Cardio-Oncology Clinic, Heart Failure Unit, Department of Cardiology, University Hospital Attikon, Athens, National and Kapodistrian University of Athens Medical School, Athens, Greece.
³ Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Free article

Editorial

Tochukwu M Okwuosa et al. Eur J Heart Fail. 2020 Nov.

Free article

. 2020 Nov;22(11):1961-1965.

doi: 10.1002/ejhf.1999. Epub 2020 Sep 29.

¹ Section of Cardio-Oncology, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.
² Cardio-Oncology Clinic, Heart Failure Unit, Department of Cardiology, University Hospital Attikon, Athens, National and Kapodistrian University of Athens Medical School, Athens, Greece.
³ Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

No abstract available

Comment on

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D. Lyon AR, et al. Eur J Heart Fail. 2020 Nov;22(11):1945-1960. doi: 10.1002/ejhf.1920. Epub 2020 Aug 6. Eur J Heart Fail. 2020. PMID: 32463967 Free PMC article.

1. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
1. Lipshultz SE, Scully R, Stevenson KE, Franco VI, Neuberg DS, Colan SD, Silverman LB, Moslehi JJ, Cheng S, Sallan SE. Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome. J Clin Oncol 2014;32:10021-10021.
1. Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, Moslehi J, Kwong RY. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 2012;110:1679-1686.
1. Agunbiade TA, Zaghlol RY, Barac A. Heart failure in relation to anthracyclines and other chemotherapies. Methodist Debakey Cardiovasc J 2019;15:243-249.